Simulations Plus (NASDAQ:SLP) Issues FY 2025 Earnings Guidance

Simulations Plus (NASDAQ:SLP) updated its FY 2025 earnings guidance on Thursday. The company provided EPS guidance of 1.070-1.200 for the period, compared to the consensus EPS estimate of 1.090. The company issued revenue guidance of $90.0 million-$93.0 million, compared to the consensus revenue estimate of $90.4 million. Simulations Plus also updated its FY25 guidance to $1.07-1.20 EPS.

Simulations Plus Stock Performance

Shares of NASDAQ SLP traded down $0.95 during mid-day trading on Thursday, hitting $23.82. The stock had a trading volume of 353,261 shares, compared to its average volume of 175,221. Simulations Plus has a twelve month low of $23.00 and a twelve month high of $51.22. The firm has a market cap of $478.59 million, a PE ratio of 59.55 and a beta of 0.89. The company has a 50 day moving average of $30.38 and a two-hundred day moving average of $30.38.

Simulations Plus (NASDAQ:SLP) last announced its quarterly earnings results on Thursday, April 3rd. The technology company reported $0.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.25 by $0.06. The firm had revenue of $22.43 million for the quarter, compared to the consensus estimate of $21.93 million. Simulations Plus had a net margin of 10.97% and a return on equity of 6.84%. The firm’s quarterly revenue was up 22.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.20 earnings per share. Equities research analysts predict that Simulations Plus will post 1.09 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the company. William Blair reiterated an “outperform” rating on shares of Simulations Plus in a report on Wednesday, January 8th. KeyCorp increased their price objective on Simulations Plus from $35.00 to $37.00 and gave the company an “overweight” rating in a research note on Friday, January 24th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $49.40.

Insider Activity at Simulations Plus

In related news, Director Walter S. Woltosz sold 20,000 shares of the business’s stock in a transaction dated Monday, February 3rd. The stock was sold at an average price of $33.91, for a total value of $678,200.00. Following the completion of the sale, the director now directly owns 3,402,584 shares of the company’s stock, valued at $115,381,623.44. The trade was a 0.58 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 19.40% of the stock is currently owned by insiders.

Simulations Plus Company Profile

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.